1. Home
  2. AUBN vs MAIA Comparison

AUBN vs MAIA Comparison

Compare AUBN & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Auburn National Bancorporation Inc.

AUBN

Auburn National Bancorporation Inc.

HOLD

Current Price

$26.28

Market Cap

92.5M

Sector

Finance

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.32

Market Cap

79.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AUBN
MAIA
Founded
1907
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
92.5M
79.0M
IPO Year
1996
2022

Fundamental Metrics

Financial Performance
Metric
AUBN
MAIA
Price
$26.28
$1.32
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
783.0
553.8K
Earning Date
04-28-2026
05-12-2026
Dividend Yield
4.61%
N/A
EPS Growth
13.66
33.33
EPS
1.29
N/A
Revenue
$619,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$20.37
N/A
Revenue Growth
0.81
N/A
52 Week Low
$21.60
$0.87
52 Week High
$28.88
$3.19

Technical Indicators

Market Signals
Indicator
AUBN
MAIA
Relative Strength Index (RSI) N/A 50.62
Support Level N/A $1.25
Resistance Level N/A $1.48
Average True Range (ATR) 0.00 0.07
MACD 0.00 0.00
Stochastic Oscillator 0.00 44.74

Price Performance

Historical Comparison
AUBN
MAIA

About AUBN Auburn National Bancorporation Inc.

Auburn National Bancorp Inc is a bank holding company registered with the Board of Governors of the Federal Reserve System (the Federal Reserve). As a bank holding company, the Company may diversify into a broader range of financial services and other business activities than are currently permitted to the Bank under applicable laws and regulations. The holding company structure also provides greater financial and operating flexibility than is presently permitted to the Bank. The Company's business is conducted through the Bank and its subsidiaries. Although it has no immediate plansto conduct any other business, the Company may engage directly or indirectly in several activities closely related to banking permitted by the Federal Reserve.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: